Skip to Main Content
Contribute Try STAT+ Today

Amid ongoing concerns over the cost of insulin, a leading physicians group is calling for a raft of measures that would increase affordability for the life-saving diabetes treatment, a move that comes as the incoming Biden administration readies its agenda for addressing prescription drug prices.

At the top of its list, the Endocrine Society would like to see the federal government negotiate pricing with drug companies, as well as place limits on future wholesale price hikes that are tied to the overall inflation rate and restrict the out-of-pocket costs borne by people with diabetes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.